Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: mindmed.co
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $20.00 | Buy | Chardan Capital Markets |
| 10/14/2024 | $20.00 | Outperform | Leerink Partners |
| 7/24/2024 | $36.00 | Buy | ROTH MKM |
| 5/29/2024 | $27.00 | Outperform | Robert W. Baird |
| 4/15/2024 | $20.00 | Outperform | Leerink Partners |
| 12/5/2023 | $9.00 | Buy | Canaccord Genuity |
| 12/9/2022 | $25.00 | Buy | ROTH Capital |
| 11/16/2022 | $5.00 | Outperform | RBC Capital Mkts |
| 8/26/2022 | $3.50 | Outperform | Oppenheimer |
| 8/10/2022 | $3.00 | Overweight | Cantor Fitzgerald |
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
144 - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
424B3 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
424B7 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
144 - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. "2024 has been a transformational year for MindMed. We've successfully executed many important milestones, including raising approximately $250 million through two equity financings, obtaining a newly issued patent covering MM120 orally disintegrating tablet (ODT) and extending intellectual property protection through 2041, expanding our pipeline to include MM120 ODT for maj
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo - - Study builds on positive Phase 2b study results presented at the American Psychiatric Association's Annual Meeting in May 2024 - - Topline data from the 12-week double-blind period anticipated in the first half of 2026 - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company's lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ. Details of the presentations are as follows: Title: Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorder Format: Poster Presenter: Paula Jacobson, Ph.D., Executive Director, Cli
- Innovation Passport Designation Aims to Accelerate Time to Market and Facilitate Patient Access to Innovative Medicines - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). The Innovation Passport is the entry point to the ILAP, which aims to accelerate time to market and facilitate patient access to med
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 171,000 common shares of the Company (the "Options"), with effective grant dates of November 18, 2024 and December 2, 2024, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the last trading day on which MindMed's common shares traded prior to the date of the respec
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies London Healthcare Conference Format: 1x1 Meetings Dates: November 20-21, 2024 Location: London, UK 7th Annual Evercore HealthCONx Conference Format: Fireside Chat and 1x1 Meetings Date and Time: Thursday, December 5, 2024 at 11:15 PM ET Location: Coral Gables, FL Webcast Link: 7th Annual Evercore HealthCONx Conference Audio webcasts and replays of av
--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the third quarter ended September 30, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after
--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the third quarter ended September 30, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after
--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024-- --Expanding pipeline with MM120 ODT clinical program in Major Depressive Disorder (MDD) with plans to initiate a registrational study in first half of 2025-- --New patent issued by the United States Patent and Trademark Office (USPTO) extends intellectual property protection for MM120 ODT through 2041-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Tuesday, August 13, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company's results for the second quarter ended June 30, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days af
--Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment-- --The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults-- --Cash and cash equivalents of $252.3 million as of March 31, 2024-- --Company to host a conference call today at 4:30 p.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the first quarter ended March 31, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days afte
-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate- -MindMed plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA) in the first half of 2024 and initiate its Phase 3 clinical program in the second half of 2024- -MindMed will host a webcast to discuss data from its Phase 2b study at 8:00 am ET- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product cand
- Data update includes 12-week topline Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) - - Results from Phase 1 pharmacokinetics bridging trial for MM120 oral dissolving tablet (ODT) formulation to be discussed - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company's Phase 2
--Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024-- --Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD)-- --Conference call to discuss year-end financial results at 8:00 a.m. EST-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health d
– Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose – – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen's d effect size = 0.88) – – Clinical response rate of 78% in 100 µg and 200 µg dose groups and 50% clinical remission rate in the 100 µg dose group at Week 4 – – MM-120 was generally well-tolerated with mostly mild-to-moderate adverse events that occurred on dosing day – – Company plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corporate Affairs Officer. Ms. Fagan will serve as a member of the executive team and will oversee public affairs and corporate communications for the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729857388/en/Stephanie Fagan, Chief Corporate Affairs Officer of MindMed (Photo: Business Wire) "I want to welcome Stephanie to the MindMed team. Stephanie's track
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective today. "MindMed's inclusion in the Russell Indexes mark an exciting milestone and reflects growing recognition of our commitment to addressing the unmet medical needs for people with brain health disorders by advancing MM120 for the treatment of general anxiety disorder and MM402 for the treatment of autism
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary. "We are very excited to welcome Mark to our management team. Mark brings tremendous legal and public company life sciences expertise and will be a strong addition to our executive team. We believe Mark's experience, insights and guidance will prove invaluable as MindMed progresses to the next stage of its evolution. I look forward to working closely with Mark during this transf
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life sciences experience will be invaluable as we advance through several key product development inflection points in the com
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence
NEW YORK, June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting"). Election of DirectorsThe five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows: Name of Nominee Votes For Votes Withheld Number of Votes Percentage of Votes Number of Votes Percentage of Votes Carol A. Vallone 66,244,518.68 89.04%
NEW YORK, May 23, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector. "We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech ca
Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00
Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00
ROTH MKM initiated coverage of MindMed with a rating of Buy and set a new price target of $36.00
Robert W. Baird initiated coverage of MindMed with a rating of Outperform and set a new price target of $27.00
Leerink Partners initiated coverage of MindMed with a rating of Outperform and set a new price target of $20.00
Canaccord Genuity initiated coverage of MindMed with a rating of Buy and set a new price target of $9.00
ROTH Capital resumed coverage of MindMed with a rating of Buy and set a new price target of $25.00
RBC Capital Mkts initiated coverage of MindMed with a rating of Outperform and set a new price target of $5.00
Oppenheimer initiated coverage of MindMed with a rating of Outperform and set a new price target of $3.50
Cantor Fitzgerald initiated coverage of MindMed with a rating of Overweight and set a new price target of $3.00
SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)